ArticleJournal of gastric cancer2026
Prognostic Model for Survival After Upfront R0 Gastrectomy in Peritoneal Oligometastatic Gastric Cancer.
Article in Journal of gastric cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Surgery for Oligometastatic Gastric Cancer: Defining Who May Benefit.Journal of gastric cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposePeritoneal metastasis from gastric cancer (GC) is generally considered incurable. Although conversion surgery is the preferred strategy, surgeons frequently encounter clinical scenarios requiring upfront surgery. Currently, objective criteria for predicting prognosis after upfront R0 gastrectomy remain undefined. MATERIALS AND
methodsThis retrospective multicenter cohort study analyzed data from 792 patients derived from the PASS-META cohort and an independent validation dataset collected between 2014 and 2021. The final analysis included 80 patients with peritoneal oligometastasis (P1/P2) who underwent upfront R0 gastrectomy for risk stratification, and 632 controls who underwent R2 gastrectomy or no gastrectomy for survival comparison. A component-wise gradient-boosting survival model was developed and simplified into an 8-item risk scoring system.
resultsThe machine learning (ML) model demonstrated robust discrimination in external validation (concordance index, 0.811; 95% confidence interval, 0.677-0.955) and stratified patients into low- and high-risk groups with significantly different survival outcomes (log-rank P<0.001), independent of systemic chemotherapy compliance. Low-risk patients achieved a 5-year survival rate exceeding 30%, whereas high-risk patients showed survival rates comparable to those of patients who underwent R2 gastrectomy or no gastrectomy. The simplified 8-item risk groups showed high concordance with the ML model risk groups (F1-score, 0.975).
conclusionsWe developed and validated a prediction model and an 8-item risk scoring system that effectively stratified patients with peritoneal oligometastatic GC according to their prognosis after upfront R0 gastrectomy. Although prospective validation is warranted, this framework provides objective prognostic guidance that may support intraoperative decision-making, distinguishing patients with favorable long-term outcomes from those whose survival is comparable to that of noncurative approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.